Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited (SUNPHARMA) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

Ask AI

Key metrics

Price as of 2026-09-02

Stock price
₹1931.70
Market cap
4,62,138 Cr
Stock P/E
37.3
P/B
5.53
Dividend yield
0.9%

Sign in for full ratios and TTM. Learn about these metrics →

Share price

NSE closing price from historical market data.

Loading price history…

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales12,192 Cr12,381 Cr11,983 Cr12,653 Cr13,291 Cr13,675 Cr12,959 Cr13,851 Cr14,478 Cr15,521 Cr14,612 Cr15,300 Cr
Operating expenses (approx.)9,013 Cr8,904 Cr8,948 Cr9,045 Cr9,352 Cr9,666 Cr9,243 Cr9,550 Cr9,951 Cr10,572 Cr10,658 Cr10,882 Cr
EBITDA3,179 Cr3,477 Cr3,035 Cr3,608 Cr3,939 Cr4,009 Cr3,716 Cr4,302 Cr4,527 Cr4,948 Cr3,954 Cr4,418 Cr
OPM %26.1%28.1%25.3%28.5%29.6%29.3%28.7%31.1%31.3%31.9%27.1%28.9%
Other income294 Cr250 Cr606 Cr533 Cr354 Cr466 Cr613 Cr464 Cr470 Cr579 Cr459 Cr724 Cr
Interest49 Cr35 Cr74 Cr62 Cr69 Cr52 Cr49 Cr75 Cr100 Cr78 Cr86 Cr100 Cr
Depreciation633 Cr622 Cr650 Cr655 Cr626 Cr631 Cr664 Cr701 Cr730 Cr732 Cr775 Cr739 Cr
Profit before tax2,775 Cr2,993 Cr2,808 Cr3,413 Cr3,605 Cr3,472 Cr3,248 Cr3,163 Cr4,155 Cr4,207 Cr3,537 Cr4,089 Cr
Tax %14.1%14.4%5.3%16.2%15.7%16.1%33.7%27.5%24.8%19.6%23.4%29.1%
Net profit2,385 Cr2,561 Cr2,659 Cr2,861 Cr3,037 Cr2,913 Cr2,154 Cr2,293 Cr3,125 Cr3,381 Cr2,710 Cr2,901 Cr
EPS (₹)₹9.90₹10.50₹11.10₹11.80₹12.70₹12.10₹9.00₹9.50₹13.00₹14.00₹11.30₹12.10

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2019BSE balance sheet (this exchange's own filing had none for this period)Mar 2020BSE balance sheet (this exchange's own filing had none for this period)Mar 2021BSE balance sheet (this exchange's own filing had none for this period)Mar 2022BSE balance sheet (this exchange's own filing had none for this period)Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales29,066 Cr32,838 Cr33,498 Cr38,654 Cr43,886 Cr48,497 Cr52,578 Cr58,462 CrSign in for TTM
Operating expenses (approx.)22,758 Cr25,848 Cr25,007 Cr28,257 Cr32,239 Cr35,474 Cr37,307 Cr40,731 CrSign in for TTM
EBITDA6,308 Cr6,990 Cr8,491 Cr10,398 Cr11,647 Cr13,023 Cr15,272 Cr17,731 CrSign in for TTM
OPM %21.7%21.3%25.3%26.9%26.5%26.9%29.0%30.3%Sign in for TTM
Other income1,025 Cr636 Cr836 Cr922 Cr635 Cr1,354 Cr1,965 Cr1,972 CrSign in for TTM
Interest555 Cr303 Cr141 Cr127 Cr172 Cr238 Cr231 Cr339 CrSign in for TTM
Depreciation1,753 Cr2,053 Cr2,080 Cr2,144 Cr2,529 Cr2,557 Cr2,575 Cr2,938 CrSign in for TTM
Profit before tax3,809 Cr4,995 Cr2,787 Cr4,465 Cr9,361 Cr11,049 Cr13,737 Cr15,063 CrSign in for TTM
Tax %15.8%16.5%18.5%24.1%9.1%13.0%20.2%23.6%Sign in for TTM
Net profit3,208 Cr4,172 Cr2,272 Cr3,389 Cr8,513 Cr9,610 Cr10,965 Cr11,509 CrSign in for TTM
EPS (₹)₹11.11₹15.69₹12.10₹13.60₹35.30₹39.90₹45.60₹47.80Sign in for TTM
Dividend payout %———64.0%29.6%30.2%33.0%34.2%Sign in for TTM
Sign in for TTM

Trailing twelve months totals and margin rows

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2019BSE balance sheet (this exchange's own filing had none for this period)Mar 2020BSE balance sheet (this exchange's own filing had none for this period)Mar 2021BSE balance sheet (this exchange's own filing had none for this period)Mar 2022BSE balance sheet (this exchange's own filing had none for this period)Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital240 Cr240 Cr240 Cr240 Cr240 Cr240 Cr240 Cr240 Cr
Reserves41,169 Cr45,025 Cr46,223 Cr47,771 Cr55,755 Cr63,427 Cr71,978 Cr83,330 Cr
Borrowings9,893 Cr7,578 Cr3,343 Cr931 Cr6,198 Cr2,846 Cr1,870 Cr4,082 Cr
Other liabilities10,078 Cr11,549 Cr14,844 Cr17,803 Cr15,230 Cr15,511 Cr17,745 Cr20,824 Cr
Total liabilities64,694 Cr68,252 Cr67,667 Cr69,800 Cr80,744 Cr85,463 Cr92,101 Cr1,08,785 Cr
Fixed assets (net)10,027 Cr10,567 Cr10,235 Cr10,371 Cr10,390 Cr10,192 Cr10,036 Cr11,114 Cr
CWIP911 Cr659 Cr937 Cr798 Cr963 Cr1,108 Cr1,234 Cr1,381 Cr
Investments7,903 Cr10,143 Cr9,612 Cr12,849 Cr14,830 Cr15,026 Cr18,354 Cr24,723 Cr
Loans & advances309 Cr148 Cr56 Cr170 Cr41 Cr65 Cr48 Cr53 Cr
Inventories7,886 Cr7,875 Cr8,997 Cr8,997 Cr10,513 Cr9,868 Cr10,243 Cr11,493 Cr
Trade receivables8,884 Cr9,421 Cr9,061 Cr10,593 Cr11,439 Cr11,249 Cr13,046 Cr15,510 Cr
Cash & bank7,062 Cr5,677 Cr6,273 Cr4,508 Cr4,624 Cr9,286 Cr10,269 Cr9,771 Cr
Other assets21,711 Cr23,762 Cr22,495 Cr21,514 Cr27,943 Cr28,669 Cr28,870 Cr34,742 Cr
Total assets64,694 Cr68,252 Cr67,667 Cr69,800 Cr80,744 Cr85,463 Cr92,101 Cr1,08,785 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2019BSE balance sheet (this exchange's own filing had none for this period)Mar 2020BSE balance sheet (this exchange's own filing had none for this period)Mar 2021BSE balance sheet (this exchange's own filing had none for this period)Mar 2022BSE balance sheet (this exchange's own filing had none for this period)Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity———8,985 Cr4,959 Cr12,135 Cr14,072 Cr12,419 Cr
Cash from investing———-5,725 Cr-7,944 Cr-690 Cr-5,306 Cr-11,344 Cr
Cash from financing———-5,193 Cr2,376 Cr-6,710 Cr-7,906 Cr-2,513 Cr
Net cash flow———-1,765 Cr115 Cr4,662 Cr983 Cr-498 Cr
Free cash flow (OCF − Capex)———7,490 Cr2,874 Cr9,933 Cr11,944 Cr8,810 Cr

Ratios

Ratios as reported or derived per annual period.

MetricMar 2019BSE balance sheet (this exchange's own filing had none for this period)Mar 2020BSE balance sheet (this exchange's own filing had none for this period)Mar 2021BSE balance sheet (this exchange's own filing had none for this period)Mar 2022BSE balance sheet (this exchange's own filing had none for this period)Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %10.5%11.7%6.3%9.6%14.6%16.1%18.8%17.5%
ROE %6.4%8.3%6.2%6.8%14.3%14.3%15.1%13.7%
Debtor days1111059810095859097
Inventory days496521532465492522578566
Days payable261271235231266299349361
Cash conversion cycle347355396333321307319301
Debt / equity0.240.170.070.020.110.040.030.05
Current ratio1.792.021.892.042.002.562.892.82
Net debt / EBITDA0.000.000.000.000.14-0.49-0.55-0.32

Compare with peers

Loading peers…

Sun Pharmaceutical Industries Limited (SUNPHARMA) Financials | BullKarma